INV441
Glioblastoma Multiforme
Pre-clinicalActive
Key Facts
About invIOs
invIOs is a Vienna-based biotech developing novel immuno-oncology therapies, with a pipeline featuring both an autologous cell therapy platform (EPiC) and a small molecule program. Its lead asset, APN401, is in Phase 1 trials for solid tumors, while other programs target glioblastoma, AML, and enhanced CAR therapies. The company is privately held, raised a €8.2M Series A, and is led by a team with deep expertise in oncology drug development and Austrian biotech.
View full company profileTherapeutic Areas
Other Glioblastoma Multiforme Drugs
| Drug | Company | Phase |
|---|---|---|
| Aldoxorubicin (LADR-7) | LadRx | Phase 2 |
| TLR-011 (Nabiximols) | Tilray | Phase 2 |
| certepetide (LSTA1) | Lisata Therapeutics | Phase 1/2 |
| WP1122 | Moleculin Biotech | Preclinical/Phase 1 |